Spyre Therapeutics, Inc. announced the dosing of the first patient in its Phase 2 SKYWAY basket trial of SPY072, an investigational anti-TL1A antibody. This trial is pioneering the study of an anti-TL1A antibody in rheumatic diseases, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).
SPY072 is designed for quarterly or twice-yearly subcutaneous dosing, aiming to offer a potential first- and best-in-class profile for these conditions. Proof-of-concept data for all three indications in the SKYWAY study are expected in 2026.
The SKYWAY trial, alongside the ongoing SKYLINE-UC platform study, is expected to provide a total of 9 proof-of-concept readouts in 2026 and 2027. This advancement signifies a major step in Spyre's strategy to address unmet needs in chronic immune-mediated diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.